Clinical Trial Search

Primary: Histologic Response in Endometrial Adenocarcinomas of the Uterine Corpus That Are Progesterone Receptor Positive Compared With Those That Are Progesterone Receptor…

Primary: Overall Survival at 2 Years and 5 Years — 93; 85 percentage of participants

Primary: Best Pathologic Responses — 17; 4; 6; 1 participants

Primary: Correlation Between Circulating Levels of These Markers and Demographic Characteristics. — 39; 42; 11; 8 Participants — p=0.026

Primary: Safety as Measured by Any Grade Treatment Related Adverse Events Experienced by ≥ 2 Patients — 10; 9; 8; 8 Participants

Primary: Cumulative CR Rates Within 16 Weeks — 23; 12 Participants

Primary: Negative Predictive Value of Sentinel Lymph Node Prediction of Metastatic Disease — 98.8 percentage of patients

Primary: Complete Response Rate - 6 Months — 80 percentage of participants

Primary: Objective Response Rates (ORR) — 74.4 percentage of participants

Primary: Percentage of Patients With Progression-free Survival > 6 Months — 10 percentage of participants

Primary: IHC-based Tissue Markers of Proliferation

Primary: Changes in Ki67 Expression After About 3 Weeks of Letrozole Treatment for Patients With Endometrial Cancer — -3.75; 1.583 percentage of Ki67 staining cells — p=0.0373

Primary: Number of Participants With Objective Response Plus Stable Disease Rate (CR + PR + SD) — 0; 0; 14; 17 participants

Primary: Tumor Response — 0; 1; 12; 11 participants

Primary: Frequency of Objective Tumor Response as Assessed by RECIST 1.1- Overall Response Rate (ORR) — 5; 9; 7; 3 Participants — p=0.024

Primary: Determination (for ITT (Intet-to-Treat Set): Efficacy of a Monthly Administration of Fulvestrant in Patients With Recurrent or Metastatic Endometrial Carcinoma by…

Primary: Change in Tumor Proliferation — -0.17 percent (represented by mean) of cells

Primary: Best Overall Response Rate (BORR) According to PI3K Activation Pathway Status — 49; 21; 70; 1 number of participants

Primary: Incidence of Adverse Effects as Assessed by the National Cancer Institute CTCAE v. 4.0 — 0; 0; 0; 3 Participants

Primary: Participant Responses — 2; 8; 4; 6 participants

Primary: Evaluate Patients With Progression Free Survival (PFS) — 26 months

Primary: Progression-free Survival Greater Than 6 Months — 31; 21 participants

Primary: Overall Response Rate/ORR of Participants — 1; 15 Participants

Primary: Number of Participants With or Without Progression-free Survival for > 6 Months by Response Evaluation Criteria for Solid Tumors (RECIST) — 39; 11 participants

Primary: Objective Response Rate (ORR) — 20 Participants

Primary: Mean Post-treatment Tumor Progesterone Receptor H-score (Histology Score) — 53.6; 42.7 units on a scale — p=0.87

Primary: Number of Participants in the DRSP/E2 Group With an Assessment of Endometrial Hyperplasia or Worse at End of Study (EoS) (1 Year of Treatment) — 0 Participants

Primary: Overall Disease Control Rate — 17 percentage of participants

Primary: The Impact in Terms of Overall Quality of Life of Adjuvant Chemotherapy by the QLQ-C30 Questionnaire — 61.7; 71.1 units on a scale

Primary: Progression-free Survival > 6 Months — 18.8 percentage of participants